Literature DB >> 22391279

Transitioning patients taking clozapine from the public to private/GP shared-care setting: barriers and criteria.

Sacha L Filia1, Alyson Wheelhouse, Stuart J Lee, Maggie Main, Anthony de Castella, Sally Wilkins, Jayashri Kulkarni.   

Abstract

OBJECTIVE: The aim of this study was to explore the barriers to transitioning patients taking clozapine from the public to private psychiatrist or general practitioner (GP) shared-care setting, as well as the criteria used by staff to identify patients suitable for transitioning.
METHOD: The experience of clinicians managing people taking clozapine was explored through circulation of a feedback questionnaire. The clozapine transition questionnaire (CTQ) was developed as the primary measure following extensive consultation with clinical staff with expertise in clozapine treatment. A total of 215 clinicians were sent questionnaires (60 community mental health service staff, 120 private psychiatrists registered to prescribe clozapine, and 35 GPs from the Bayside Health clozapine GP shared-care programme), with overall 80 (46.2%) returned.
RESULTS: Over 64% of participants had managed patients who had been transitioned from public to private psychiatrist or GP shared-care settings. Around half of these said that it was a 'worthwhile treatment option' and that 'it went smoothly' and 'the patient was satisfied'. The most significant barriers to successful transitioning were the cost of private service, the patient's level of disorganization, and the need for ongoing care coordination. The most important criteria for transitioning patients was compliance with medication, ability to independently attend appointments and access appropriate pharmacies to receive medication, and willingness to transition out of the public system.
CONCLUSIONS: Transitioning suitable public psychiatric patients taking clozapine into private psychiatrist/GP shared-care offers an important model to improve the efficiency and effectiveness of care, but requires careful planning, preparation, and monitoring to ensure sustained success.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22391279     DOI: 10.1177/0004867411433210

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  6 in total

Review 1.  Clozapine in primary care.

Authors:  Karl Winckel; Dan Siskind
Journal:  Aust Prescr       Date:  2017-12-04

2.  Compliance with pathology testing guidelines in Australian general practice: protocol for a secondary analysis of electronic health record data.

Authors:  Gorkem Sezgin; Andrew Georgiou; Rae-Anne Hardie; Ling Li; Lisa G Pont; Tony Badrick; Guilherme S Franco; Johanna I Westbrook; Natalie Rinehart; Adam McLeod; Christopher Pearce; Marianne Shearer; Robin Whyte; Elizabeth Deveny
Journal:  BMJ Open       Date:  2018-11-13       Impact factor: 2.692

3.  Implementing a clozapine supply service in Australian community pharmacies: barriers and facilitators.

Authors:  Bethany Wilson; Sara S McMillan; Amanda J Wheeler
Journal:  J Pharm Policy Pract       Date:  2019-08-07

Review 4.  Use of Primary Care Data in Research and Pharmacovigilance: Eight Scenarios Where Prescription Data are Absent.

Authors:  Grace N Okoli; Puja Myles; Tarita Murray-Thomas; Hilary Shepherd; Ian C K Wong; Duncan Edwards
Journal:  Drug Saf       Date:  2021-07-22       Impact factor: 5.606

5.  An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.

Authors:  Nawaz Hack; Sarah M Fayad; Erin H Monari; Umer Akbar; Angela Hardwick; Ramon L Rodriguez; Irene A Malaty; Janet Romrell; Aparna A Wagle Shukla; Nikolaus McFarland; Herbert E Ward; Michael S Okun
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

6.  Cross-sector user and provider perceptions on experiences of shared-care clozapine: a qualitative study.

Authors:  Camilla Sowerby; Denise Taylor
Journal:  BMJ Open       Date:  2017-09-28       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.